Can-Fite details Namodenoson patient outcome in 6-K

Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements.

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.

The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Can-Fite BioPharma (CANF) report in this Form 6-K?

Can-Fite BioPharma filed a Form 6-K to furnish a press release titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson” and to incorporate the first paragraph of that release into several existing Form S-8 and Form F-3 registration statements.

What clinical result does Can-Fite (CANF) highlight regarding Namodenoson?

The press release referenced in the filing reports a complete resolution of esophageal varices in a decompensated cirrhosis patient treated with Namodenoson, according to the title of the release furnished as Exhibit 99.1.

How does this Form 6-K affect Can-Fite BioPharma’s (CANF) registration statements?

The filing states that the first paragraph of the press release is incorporated by reference into Can-Fite’s Form S-8 and Form F-3 registration statements, making that information part of the disclosure package for those securities offerings from the date of this report.

Which exhibits are included with Can-Fite BioPharma’s (CANF) September 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is the press release dated September 15, 2025 describing the reported clinical outcome in a decompensated cirrhosis patient treated with Namodenoson.

Who signed the Can-Fite BioPharma (CANF) Form 6-K?

The Form 6-K was signed on behalf of Can-Fite BioPharma Ltd. by Motti Farbstein, who is identified as the company’s Chief Executive Officer and Chief Financial Officer.

Why is Can-Fite (CANF) using a Form 6-K for this update?

As a foreign private issuer, Can-Fite uses Form 6-K to provide current information to U.S. investors. In this case, the form is used to furnish a press release about a reported clinical outcome and to formally integrate part of that information into existing registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 07:10 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

The first paragraph of the press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

On September 15, 2025, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson”. A copy of this press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated September 15, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: September 15, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3